DK3733187T3 - Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer - Google Patents

Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer Download PDF

Info

Publication number
DK3733187T3
DK3733187T3 DK20181616.2T DK20181616T DK3733187T3 DK 3733187 T3 DK3733187 T3 DK 3733187T3 DK 20181616 T DK20181616 T DK 20181616T DK 3733187 T3 DK3733187 T3 DK 3733187T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
chiral diaryl
macrocycle
diaryl macrocycle
Prior art date
Application number
DK20181616.2T
Other languages
English (en)
Inventor
Jingrong Jean Cui
Yishan Li
Evan W Rogers
Dayong Zhai
Wei Deng
Zhongdong Huang
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Application granted granted Critical
Publication of DK3733187T3 publication Critical patent/DK3733187T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK20181616.2T 2015-07-21 2016-07-20 Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer DK3733187T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195081P 2015-07-21 2015-07-21
US201662302231P 2016-03-02 2016-03-02
EP16828471.9A EP3325488B1 (en) 2015-07-21 2016-07-20 Chiral diaryl macrocycle and use thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3733187T3 true DK3733187T3 (da) 2025-01-02

Family

ID=57834656

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20181616.2T DK3733187T3 (da) 2015-07-21 2016-07-20 Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer
DK16828471.9T DK3325488T3 (da) 2015-07-21 2016-07-20 Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16828471.9T DK3325488T3 (da) 2015-07-21 2016-07-20 Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer

Country Status (24)

Country Link
US (4) US20180325901A1 (da)
EP (3) EP3325488B1 (da)
JP (1) JP6817287B2 (da)
KR (1) KR102772574B1 (da)
CN (1) CN108026109B (da)
AU (1) AU2016296878B2 (da)
BR (1) BR112018001065A2 (da)
CA (1) CA2992324A1 (da)
DK (2) DK3733187T3 (da)
ES (2) ES2993492T3 (da)
FI (1) FI3733187T3 (da)
HR (1) HRP20241615T1 (da)
HU (1) HUE070316T2 (da)
IL (1) IL256868B (da)
LT (1) LT3733187T (da)
MX (1) MX383823B (da)
PL (1) PL3733187T3 (da)
PT (1) PT3733187T (da)
RS (1) RS66238B1 (da)
RU (2) RU2728579C2 (da)
SI (1) SI3733187T1 (da)
SM (1) SMT202400496T1 (da)
WO (1) WO2017015367A1 (da)
ZA (1) ZA201800416B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107267458B (zh) * 2017-07-06 2019-10-29 中南大学湘雅二医院 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
AU2018364938B2 (en) * 2017-11-10 2021-11-11 Angex Pharmaceutical, Inc. Macrocyclic compounds as TRK kinase inhibitors and uses thereof
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2019184955A1 (en) * 2018-03-28 2019-10-03 Fochon Pharmaceuticals, Ltd. Macrocyclic compounds as trk kinases inhibitors
WO2019201131A1 (zh) * 2018-04-16 2019-10-24 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
CN111902417B (zh) * 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
WO2020257169A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
CN111689883B (zh) * 2020-05-22 2022-02-11 上海应用技术大学 一种二芳基砜类化合物的合成方法
EP4163283A1 (en) * 2020-06-04 2023-04-12 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
CN115813930A (zh) * 2021-08-17 2023-03-21 赛诺哈勃药业(成都)有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
WO2025217347A2 (en) * 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
PT657458E (pt) * 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ATE301661T1 (de) * 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
KR20110073500A (ko) * 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) * 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
DK2822953T5 (da) 2012-03-06 2017-09-11 Pfizer Makrocykliske derivater til behandling af proliferative sygdomme
WO2013134219A1 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途

Also Published As

Publication number Publication date
SI3733187T1 (sl) 2025-01-31
ES2993492T3 (en) 2025-01-02
RS66238B1 (sr) 2024-12-31
US12310968B2 (en) 2025-05-27
US20250375451A1 (en) 2025-12-11
US20210030756A1 (en) 2021-02-04
FI3733187T3 (fi) 2024-12-18
IL256868B (en) 2021-03-25
US20230346786A1 (en) 2023-11-02
SMT202400496T1 (it) 2025-01-14
US20180325901A1 (en) 2018-11-15
HRP20241615T1 (hr) 2025-01-31
JP6817287B2 (ja) 2021-01-20
JP2018524382A (ja) 2018-08-30
RU2020123800A (ru) 2020-10-02
BR112018001065A2 (pt) 2018-09-11
RU2018106245A3 (da) 2019-12-26
IL256868A (en) 2018-03-29
CN108026109B (zh) 2021-03-02
AU2016296878B2 (en) 2020-12-17
KR20180033194A (ko) 2018-04-02
US11452725B2 (en) 2022-09-27
LT3733187T (lt) 2024-12-10
CN108026109A (zh) 2018-05-11
HK1254606A1 (zh) 2019-07-26
MX383823B (es) 2025-03-14
EP3325488A4 (en) 2019-04-24
PT3733187T (pt) 2024-11-08
RU2018106245A (ru) 2019-08-21
DK3325488T3 (da) 2020-09-14
ES2818528T3 (es) 2021-04-13
MX2018000718A (es) 2020-01-20
ZA201800416B (en) 2021-07-28
EP4480543A2 (en) 2024-12-25
EP3733187B1 (en) 2024-10-16
EP3325488B1 (en) 2020-06-24
EP3733187A1 (en) 2020-11-04
AU2016296878A1 (en) 2018-01-25
NZ738832A (en) 2024-08-30
WO2017015367A1 (en) 2017-01-26
EP4480543A3 (en) 2025-02-12
RU2728579C2 (ru) 2020-07-30
HUE070316T2 (hu) 2025-05-28
CA2992324A1 (en) 2017-01-26
EP3325488A1 (en) 2018-05-30
PL3733187T3 (pl) 2025-01-07
KR102772574B1 (ko) 2025-02-24

Similar Documents

Publication Publication Date Title
DK3733187T3 (da) Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3076972T3 (da) Cancerbehandling med kombination af plinabulin og taxan
DK3371152T3 (da) Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer
DK3439663T3 (da) Fremgangsmåder til behandling af pædiatriske cancere
DK3174559T3 (da) Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
DK3416945T3 (da) 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
DK3258964T3 (da) Detektion og behandling af maligne tumorer i CNS
DK3383871T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i behandling af cancer
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer